Gefitinib improves survival compared with standard chemotherapy in lung cancer patients with genetic mutation

December 20, 2009

Patients with the most common form of lung cancer (non-small-cell lung cancer) who have mutations in the epidermal growth factor receptor (EGFR) gene have significantly improved progression-free survival if they are treated with gefitinib compared with standard chemotherapy. Wherever possible, EGFR genetic testing must be done and gefitinib should be considered as the first-line treatment for patients with EGRF mutations, concludes an Article published Online First in The Lancet Oncology.

Non-small-cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, and remains the leading cause of cancer death worldwide. Recently, targeted drugs have been developed that can improve survival in specific groups of patients with NSCLC. For example, gefitinib has been shown to have considerable benefit in patients with NSCLC who are more likely to have EGFR mutations, such as those of Asian origin, women, and those who have never smoked. Recent trials of gefitinib monotherapy have failed to show any survival advantage in unselected patient populations. It has been suggested that this lack of survival advantage might be due to a lack of patient selection.

To resolve this uncertainty, Tetsuya Mitsudomi and colleagues from West Japan Oncology Group compared gefitinib with a standard chemotherapy regimen (cisplatin plus docetaxel) in patients with NSCLC selected according to EGRF mutation status. 177 patients with EGFR mutations were recruited from 36 centres in Japan and randomly assigned to receive either gefitinib (88) or cisplatin plus docetaxel (89) every 21 days for 3 to 6 cycles. Disease progression was regularly assessed using CT and MRI.

Overall, patients in the gefitinib group had significantly longer progression-free survival (9.2 months) compared with the chemotherapy group (6.3 months).

In addition, findings showed that the objective response rate* was significantly higher in the gefitinib group (62.1%) than in the cisplatin plus docetaxel group (32.2%). The disease control rate was also higher in the gefitinib group (93.1%) than in the chemotherapy group (78%).

Gefitinib was also generally better tolerated than cisplatin plus docetaxel, and adverse events of grade 3 or more were infrequent and included skin rash, liver dysfunction, and diarrhoea. By contrast, the most common adverse events in the chemotherapy group occurred in more than half of patients and included nausea, myelosuppression, fatigue, and alopecia.

The authors say: "Our study indicates that EGFR genetic testing is feasible and should be done when possible...Considering the efficacy and toxicity of gefitinib, it is a reasonable option for the first-line treatment of patients with activating EGFR mutations."

They conclude: "These results strongly suggest that the presence of EGFR mutations, and not the clinical background of patients, determines clinical efficacy, and this knowledge should lead to molecularly based, personalised treatment of lung cancer in the near future."
-end-
Dr Tetsuya Mitsudomi, Aichi Cancer Center Hospital, Nagoya, Japan.
T) +82 52 762 6111 E) mitsudom@aichi-cc.jp

For full Article see: http://press.thelancet.com/tlogefitinib.pdf

Notes to Editors: * Objective response rate--the proportion of treated people in whom a complete or partial response is observed.

Lancet

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.